Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited SettingBin Wu, Wei Xue, Baijun Dong et al.|PLoS ONE|2012Cited by 109